Adverse events316

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 316

Type	Event	Organ system	Group	Affected	At risk	Events
other	White blood cell count decreased	Investigations	Phase I - Cohort 1 (Pomalidomide 2mg)	3	6	3
other	White blood cell count decreased	Investigations	Phase I - Cohort 2 (Pomalidomide 3mg)	0	3	0
other	White blood cell count decreased	Investigations	Phase I - Cohort 3 (Pomalidomide 4mg)	1	6	4
other	White blood cell count decreased	Investigations	Phase II Expansion- Maximum Tolerated Dose	10	12	15
other	wheezing	Respiratory, thoracic and mediastinal disorders	Phase I - Cohort 1 (Pomalidomide 2mg)	0	6	0
other	wheezing	Respiratory, thoracic and mediastinal disorders	Phase I - Cohort 2 (Pomalidomide 3mg)	1	3	1
other	wheezing	Respiratory, thoracic and mediastinal disorders	Phase I - Cohort 3 (Pomalidomide 4mg)	2	6	2
other	wheezing	Respiratory, thoracic and mediastinal disorders	Phase II Expansion- Maximum Tolerated Dose	0	12	0
other	weakness	General disorders	Phase I - Cohort 1 (Pomalidomide 2mg)	3	6	3
other	weakness	General disorders	Phase I - Cohort 2 (Pomalidomide 3mg)	1	3	1
other	weakness	General disorders	Phase I - Cohort 3 (Pomalidomide 4mg)	3	6	4
other	weakness	General disorders	Phase II Expansion- Maximum Tolerated Dose	4	12	5
other	vomiting	Gastrointestinal disorders	Phase I - Cohort 1 (Pomalidomide 2mg)	1	6	1
other	vomiting	Gastrointestinal disorders	Phase I - Cohort 2 (Pomalidomide 3mg)	0	3	0
other	vomiting	Gastrointestinal disorders	Phase I - Cohort 3 (Pomalidomide 4mg)	3	6	3
other	vomiting	Gastrointestinal disorders	Phase II Expansion- Maximum Tolerated Dose	2	12	2
other	visual blurring	Eye disorders	Phase I - Cohort 1 (Pomalidomide 2mg)	4	6	4
other	visual blurring	Eye disorders	Phase I - Cohort 2 (Pomalidomide 3mg)	0	3	0
other	visual blurring	Eye disorders	Phase I - Cohort 3 (Pomalidomide 4mg)	1	6	1
other	visual blurring	Eye disorders	Phase II Expansion- Maximum Tolerated Dose	3	12	3

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01570387/events

API reference For AI assistants

Adverse events316

Sources 3

Read this list from software.